TrueHealth Medical

TrueHealth Medical (真健康医疗, 02697.HK) is a Guangdong-based surgical robotics company founded in 2018 that went public on the Hong Kong Stock Exchange on June 30, 2026, pricing at HK$126.20 and surging 179.71% at the open to a market cap exceeding HK$12.5 billion . It positions itself as China's "first listed company for puncture surgical robots," specializing in full-chain self-developed percutaneous puncture and ablation surgical robots for tumor minimally invasive diagnosis and treatment .

The company's core product, the TH-S navigation and positioning system for puncture surgery, was designated "domestic first" by China's National Medical Products Administration, while its TH-X MW microwave ablation system received an "international first" designation . By 2025 shipment volume, TrueHealth held a 36.4% domestic market share in percutaneous puncture surgical robots, ranking first for three consecutive years since 2022; its products have entered nearly 100 medical institutions nationwide with over 7,200 completed surgeries . The company is now pursuing CE marking for European market entry, with approval expected in Q4 2026 . Gaorong Ventures participated in its Series A round in 2021 and continued to invest in its A+ round .